| Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy … J Datta, X Dai, A Bianchi, IDC Silva, S Mehra, VT Garrido, P Lamichhane, ... Gastroenterology 163 (6), 1593-1612, 2022 | 92 | 2022 |
| A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma C Han, S Bellone, ER Siegel, G Altwerger, G Menderes, E Bonazzoli, ... Gynecologic oncology 149 (3), 585-591, 2018 | 74 | 2018 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 72 | 2019 |
| Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences 116 (2), 619-624, 2019 | 68 | 2019 |
| Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer A Bianchi, I De Castro Silva, NU Deshpande, S Singh, S Mehra, ... Cancer discovery 13 (6), 1428-1453, 2023 | 62 | 2023 |
| Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan … E Perrone, S Lopez, B Zeybek, S Bellone, E Bonazzoli, S Pelligra, ... Frontiers in Oncology 10, 118, 2020 | 50 | 2020 |
| Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan B Zeybek, A Manzano, A Bianchi, E Bonazzoli, S Bellone, N Buza, P Hui, ... Scientific reports 10 (1), 973, 2020 | 49 | 2020 |
| PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib A Bianchi, S Lopez, G Altwerger, S Bellone, E Bonazzoli, L Zammataro, ... Gynecologic oncology 155 (1), 144-150, 2019 | 45 | 2019 |
| Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas S Lopez, E Perrone, S Bellone, E Bonazzoli, B Zeybek, C Han, ... Oncotarget 11 (5), 560, 2020 | 40 | 2020 |
| Targeting tumor–stromal IL6/STAT3 signaling through IL1 receptor inhibition in pancreatic cancer AR Dosch, S Singh, X Dai, S Mehra, IDC Silva, A Bianchi, S Srinivasan, ... Molecular cancer therapeutics 20 (11), 2280-2290, 2021 | 39 | 2021 |
| In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial … G Altwerger, E Bonazzoli, S Bellone, T Egawa-Takata, G Menderes, ... Molecular cancer therapeutics 17 (5), 1003-1011, 2018 | 33 | 2018 |
| Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial … E Perrone, P Manara, S Lopez, S Bellone, E Bonazzoli, A Manzano, ... Molecular oncology 14 (3), 645-656, 2020 | 31 | 2020 |
| In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma C Han, E Perrone, B Zeybek, S Bellone, J Tymon-Rosario, G Altwerger, ... Gynecologic oncology 156 (2), 430-438, 2020 | 31 | 2020 |
| Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer J Datta, A Bianchi, I De Castro Silva, NU Deshpande, LL Cao, S Mehra, ... Oncogene 41 (28), 3640-3654, 2022 | 29 | 2022 |
| Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized … I de Castro Silva, A Bianchi, NU Deshpande, P Sharma, S Mehra, ... Elife 11, e78921, 2022 | 26 | 2022 |
| Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer E Bonazzoli, F Predolini, E Cocco, S Bellone, G Altwerger, G Menderes, ... Clinical Cancer Research 24 (19), 4845-4853, 2018 | 25 | 2018 |
| PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers E Bonazzoli, E Cocco, S Lopez, S Bellone, L Zammataro, A Bianchi, ... Gynecologic oncology 153 (1), 158-164, 2019 | 21 | 2019 |
| Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high … G Menderes, E Bonazzoli, S Bellone, G Altwerger, JD Black, K Dugan, ... Gynecologic oncology 147 (1), 145-152, 2017 | 21 | 2017 |
| Tumor cell–intrinsic p38 MAPK signaling promotes IL1α-mediated stromal inflammation and therapeutic resistance in pancreatic cancer SP Singh, AR Dosch, S Mehra, I De Castro Silva, A Bianchi, VT Garrido, ... Cancer research 84 (8), 1320-1332, 2024 | 14 | 2024 |
| Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers AR Dosch, WK Chatila, Y Ban, A Bianchi, NU Deshpande, IDC Silva, ... Oncotarget 12 (20), 2104, 2021 | 6 | 2021 |
